NeoGenomics Inc. [NEO] has traded in a range of $19.40 to $41.17 in the last 1 year. As of this writing, the stock is at $43.27, up 5.46%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, NEO shares are 10.92% up with the monthly amount drift of 22.75% and seems well in a long time frame.

On 13, October 2020, NeoGenomics Announces Plans to Expand Global Footprint in Pharma Services by Opening Clinical Research Laboratory in Suzhou, China. According to news published on Yahoo Finance, NeoGenomics continues to build its world-class pharma clinical research capabilities to include servicing Greater China-based clinical trials.

Analyst Birdseye View:

The most recent analyst activity for NeoGenomics Inc. [NASDAQ:NEO] stock was on August 28, 2020, when it was Initiated with a Buy rating from Guggenheim, which also raised its 12-month price target on the stock to $46. Before that, on September 09, 2020, Morgan Stanley Recapitulated an Overweight rating and elevated its amount target to $46. On July 29, 2020, Needham Reiterated a Buy rating and boosted its price target on this stock from $33 to $39. On June 25, 2020, BofA/Merrill Initiated a Buy rating and increased its price target to $34. On April 21, 2020, Stephens Resumed an Overweight rating and increased its price target to $33. On March 02, 2020, Craig Hallum Resumed a Buy rating and boosted its amount on this stock to $38. On February 28, 2020, First Analysis Sec Upgrade a Strong buy rating. On January 23, 2020, First Analysis Sec Downgrade an Outperform rating and improved its amount target to $35.

In the past 52 weeks of trading, this stock has oscillated between a low of $19.40 and a peak of $41.17. Right now, according to Wall Street analyst the average 12-month amount target is $42.61. At the most recent market close, shares of NeoGenomics Inc. [NASDAQ:NEO] were valued at $43.27. According to the average price forecast, investors can expect a potential return of -0.14%.

FUNDAMENTAL ANALYSIS

NeoGenomics Inc. [NASDAQ:NEO] most recently reported quarterly sales of 86.98 billion, which represented growth of -14.50%. This publicly-traded organization’s revenue is $240,488 per employee, while its income is $4,709 per employee. This company’s Gross Margin is currently 43.30%, its Operating Margin is -4.80%, its Pretax Margin is +0.89, and its Net Margin is +1.96. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 1.32, 1.93, 3.02 and 1.53 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 20.75 and the whole liability to whole assets at 18.73. It shows enduring liability to the whole principal at 18.60 and enduring liability to assets at 0.17 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 42.28 points at 1st support level, the second support level is making up to 41.29. But as of 1st resistance point, this stock is sitting at 44.24 and at 45.21 for 2nd resistance point.

NeoGenomics Inc. [NEO] reported its earnings at -$0.04 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.1/share signifying the difference of 0.06 and 60.00% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.02 calling estimates for $0.02/share with the difference of -0.04 depicting the surprise of -200.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for NeoGenomics Inc. [NASDAQ:NEO] is 6.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.71. Now if looking for a valuation of this stock’s amount to sales ratio it’s 7.41 and it’s amount to book ratio is 6.04.

Insider Stories

The most recent insider trade was by JONES STEVEN C, Director, and it was the sale of 0.14 million shares on Sep 29. JONES STEVEN C, the Director, completed a sale of 81000.0 shares on Sep 29. On Sep 28, JONES STEVEN C, Director, completed a sale of 38951.0 shares.